Find Oxethazaine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Oxetacaine, 126-27-2, Oxethacaine, Mucaine, Oxaethacainum, Betalgil
Molecular Formula
C28H41N3O3
Molecular Weight
467.6  g/mol
InChI Key
FTLDJPRFCGDUFH-UHFFFAOYSA-N
FDA UNII
IP8QT76V17

Oxethazaine
Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at low pH levels. Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal ulcer. Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations. It is also in the list of approved derivatives of herbal products by the EMA.
1 2D Structure

Oxethazaine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[2-hydroxyethyl-[2-[methyl-(2-methyl-1-phenylpropan-2-yl)amino]-2-oxoethyl]amino]-N-methyl-N-(2-methyl-1-phenylpropan-2-yl)acetamide
2.1.2 InChI
InChI=1S/C28H41N3O3/c1-27(2,19-23-13-9-7-10-14-23)29(5)25(33)21-31(17-18-32)22-26(34)30(6)28(3,4)20-24-15-11-8-12-16-24/h7-16,32H,17-22H2,1-6H3
2.1.3 InChI Key
FTLDJPRFCGDUFH-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(CC1=CC=CC=C1)N(C)C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC2=CC=CC=C2
2.2 Other Identifiers
2.2.1 UNII
IP8QT76V17
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2,2'-((2-hydroxyethyl)imino)bis(n-alpha,alpha-dimethylphenethyl)-n-methylacetamide

2. Mucaine

3. Muthesa

4. Oxaine

5. Oxetacain

6. Oxethazaine Hydrochloride

7. Oxethazaine Monohydrochloride

8. Oxethazine

9. Robercain R

10. Tepilta

2.3.2 Depositor-Supplied Synonyms

1. Oxetacaine

2. 126-27-2

3. Oxethacaine

4. Mucaine

5. Oxaethacainum

6. Betalgil

7. Strocain

8. Emoren

9. Oxethazine

10. Oxetacaine [inn]

11. Wy-806

12. Acetamide, 2,2'-((2-hydroxyethyl)imino)bis(n-(1,1-dimethyl-2-phenylethyl)-n-methyl-

13. Nsc-758444

14. Chembl127592

15. Ip8qt76v17

16. 2-[2-hydroxyethyl-[2-[methyl-(2-methyl-1-phenylpropan-2-yl)amino]-2-oxoethyl]amino]-n-methyl-n-(2-methyl-1-phenylpropan-2-yl)acetamide

17. Chebi:31947

18. Oxetacaine (inn)

19. 2,2'-((2-hydroxyethyl)imino)bis(n-(1,1-dimethyl-2-phenylethyl)-n-methylacetamide)

20. Acetamide, 2,2'-[(2-hydroxyethyl)imino]bis[n-(1,1-dimethyl-2-phenylethyl)-n-methyl-

21. Ncgc00016382-01

22. Cas-126-27-2

23. Dsstox_cid_5818

24. Dsstox_rid_77936

25. Dsstox_gsid_25818

26. Oxethacaina [italian]

27. Milzine

28. Oxetacainum [inn-latin]

29. Oxetacaina [inn-spanish]

30. Ccris 4692

31. Sr-05000001851

32. Einecs 204-780-5

33. Fh 099

34. Wy 806

35. Oxethazaine [usan:jan]

36. Brn 2404063

37. Unii-ip8qt76v17

38. Prestwick_767

39. Spectrum_001657

40. 2-di(n-methyl-n-phenyl-tert-butyl-carbamoylmethyl)aminoethanol

41. Oxethazaine [mi]

42. Prestwick0_000058

43. Prestwick1_000058

44. Prestwick2_000058

45. Prestwick3_000058

46. Spectrum2_001987

47. Spectrum3_001751

48. Spectrum4_000202

49. Spectrum5_001269

50. Oxethazaine [jan]

51. N,n-bis(n-methyl-n-phenyl-tert-butylacetamido)-beta-hydroxyethylamine

52. Oxethazaine [usan]

53. Cid_4621

54. Oxetacaine [mart.]

55. 2,2'-((2-hydroxyethyl)imino)bis(n-(alpha,alpha-dimethylphenethyl)-n-methylacetamide)

56. Oxetacaine [who-dd]

57. Oxethazaine (jp17/usan)

58. Schembl24489

59. Bspbio_000215

60. Bspbio_003482

61. Kbiogr_000803

62. Kbioss_002137

63. 4-12-00-02822 (beilstein Handbook Reference)

64. Mls002154188

65. Divk1c_000715

66. Spectrum1503279

67. Spbio_002136

68. Spbio_002173

69. Bpbio1_000237

70. Oxethazaine, Analytical Standard

71. Dtxsid0025818

72. Hms502d17

73. Kbio1_000715

74. Kbio2_002137

75. Kbio2_004705

76. Kbio2_007273

77. Kbio3_002702

78. Ninds_000715

79. Hms1568k17

80. Hms1922a04

81. Hms2093c15

82. Hms2095k17

83. Hms2236a03

84. Hms3370m13

85. Hms3712k17

86. Hms3885p21

87. Pharmakon1600-01503279

88. Bcp07626

89. Hy-b0955

90. Zinc3874585

91. Tox21_110407

92. Bdbm50017672

93. Ccg-39525

94. Nsc758444

95. Akos024284189

96. Tox21_110407_1

97. Cs-4432

98. Db12532

99. Nsc 758444

100. Acetamide, 2,2'-((2-hydroxyethyl)imino)bis(n-(alpha,alpha-dimethylphenethyl)-n-methyl-

101. Idi1_000715

102. Ncgc00016382-02

103. Ncgc00016382-03

104. Ncgc00016382-04

105. Ncgc00016382-07

106. Ncgc00016382-09

107. Ncgc00095039-01

108. Ncgc00095039-02

109. Ncgc00095039-03

110. N-(1,1-dimethyl-2-phenyl-ethyl)-2-[[2-[(1,1-dimethyl-2-phenyl-ethyl)-methyl-amino]-2-oxo-ethyl]-(2-hydroxyethyl)amino]-n-methyl-acetamide

111. Smr001233479

112. Sbi-0051816.p002

113. Db-041818

114. Ab00052348

115. Ft-0603332

116. Sw196906-3

117. D01152

118. Ab00052348_08

119. Ab00052348_09

120. 126o272

121. J-005353

122. Q2412605

123. Sr-05000001851-1

124. Sr-05000001851-3

125. Brd-k56940463-001-05-4

126. Brd-k56940463-001-08-8

127. 2-hydroxyethyliminobis(n-[alpha,alpha-dimethylphenethyl]-n-methylacetamide)

128. 2,2'-(2-hydroxyethylazanediyl)bis(n-methyl-n-(2-methyl-1-phenylpropan-2-yl)acetamide)

129. 2,2'-((2-hydroxyethyl)imino)bis(n-(.alpha.,.alpha.-dimethylphenethyl)-n-methylacetamide)

130. N-(1,1-dimethyl-2-phenyl-ethyl)-2-[{[(1,1-dimethyl-2-phenyl-ethyl)-methyl-carbamoyl]-methyl}-(2-hydroxy-ethyl)-amino]-n-methyl-acetamide

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 467.6 g/mol
Molecular Formula C28H41N3O3
XLogP33.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count12
Exact Mass467.31479218 g/mol
Monoisotopic Mass467.31479218 g/mol
Topological Polar Surface Area64.1 Ų
Heavy Atom Count34
Formal Charge0
Complexity585
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Oxetacaine is available as an over-the-counter antacid and it is used to alleviate pain associated with gastritis, peptic ulcer disease, heartburn, esophagitis, hiatus hernia, and anorexia.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Oxetacaine improves common gastrointestinal symptoms. Oxetacaine is part of the anesthetic antacids which increase the gastric pH while providing relief from pain for a longer period of duration at a lower dosage. This property has been reported to relieve the symptoms of hyperacidity. Oxetacaine is reported to produce a reversible loss of sensation and to provide a prompt and prolonged relief of pain. In vitro, oxetacaine was showed to produce an antispasmodic action on the smooth muscle and block the action of serotonin. The local efficacy of oxetacaine has been proven to be 2000 times more potent than lignocaine and 500 times more potent than cocaine. Its anesthetic action produces the loss of sensation which can be explained by its inhibitory activity against the nerve impulses and de decrease in permeability of the cell membrane.


5.2 MeSH Pharmacological Classification

Anesthetics, Local

Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)


5.3 ATC Code

C - Cardiovascular system

C05 - Vasoprotectives

C05A - Agents for treatment of hemorrhoids and anal fissures for topical use

C05AD - Local anesthetics

C05AD06 - Oxetacaine


5.4 Absorption, Distribution and Excretion

Absorption

A peak plasma concentration of oxetacaine of approximately 20 ng/ml is attained about one hour after oral administration. LEss than 1/3 of the administered dose is absorbed as it undergoes extensive metabolism.


Route of Elimination

Less than 0.1% of the amdinistered dose is recovered in urine within 24 hours in the form of unchanged oxetacaine or its metabolites.


Volume of Distribution

This pharmacokinetic property has not been studied.


Clearance

This pharmacokinetic property has not been studied.


5.5 Metabolism/Metabolites

Oxetacaine is rapidly and extensively metabolized hepatically. After metabolism, there is a formation of primary metabolites such as beta-hydroxy-mephentermine and beta-hydroxy-phentermine. The major metabolites are found in the plasma in insignificant amounts.


5.6 Biological Half-Life

Oxetacaine presents a very short half-life of approximately one hour.


5.7 Mechanism of Action

Oxetacaine inhibits gastric acid secretion by suppressing gastrin secretion. Moreover, oxetacaine exerts a local anesthetic effect on the gastric mucosa. This potent local anesthetic effect of oxetacaine may be explained by its unique chemical characteristics in which, as a weak base, it is relatively non-ionized in acidic solutions whereas its hydrochloride salt is soluble in organic solvents and it can penetrate cell membranes. Oxetacaine diminishes the conduction of sensory nerve impulses near the application site which in order reduces the permeability of the cell membrane to sodium ions. This activity is performed by the incorporation of the unionized form into the cell membrane.


EU WC

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Oxetacaine BP

Date of Issue : 2022-06-07

Valid Till : 2022-07-07

Written Confirmation Number : WC-0104A5-A6

Address of the Firm : #125 & 126, Sipcot Industrial Complex, Hosur-635 126, Tamilnadu

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Oxetacaine BP

Date of Issue : 2022-09-30

Valid Till : 2025-09-10

Written Confirmation Number : WC-0243

Address of the Firm : Sathammai Village, Karunkuzhi Post, Madhuranthagam Taluk, Kancheepuram District,...

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Oxetacaine (BP)

Date of Issue : 2019-09-11

Valid Till : 2022-09-10

Written Confirmation Number : WC-243

Address of the Firm : Sathammai Village, Karunkuzhi Post, Madhranthagam Taluk,  Kancheepuram District...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1628188200,"product":"OXETACAINE BP (OXETHAZAINE)","address":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST","city":"MUMBAI, MAHARASHTRA.","supplier":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"CHONG DAH PHARMACEUTICAL ","customerCountry":"TAIWAN","quantity":"7.50","actualQuantity":"7.5","unit":"KGS","unitRateFc":"278.1","totalValueFC":"2026","currency":"USD","unitRateINR":20035.168000000001,"date":"06-Aug-2021","totalValueINR":"150263.76","totalValueInUsd":"2026","indian_port":"MADRAS AIR","hs_no":"29420090","bill_no":"3670694","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRAS AIR","supplierAddress":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST, MUMBAI, MAHARASHTRA.","customerAddress":""}]
06-Aug-2021
06-Aug-2021
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Oxethazaine Manufacturers

A Oxethazaine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oxethazaine, including repackagers and relabelers. The FDA regulates Oxethazaine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oxethazaine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Oxethazaine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Oxethazaine Suppliers

A Oxethazaine supplier is an individual or a company that provides Oxethazaine active pharmaceutical ingredient (API) or Oxethazaine finished formulations upon request. The Oxethazaine suppliers may include Oxethazaine API manufacturers, exporters, distributors and traders.

click here to find a list of Oxethazaine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Oxethazaine JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Oxethazaine Drug Master File in Japan (Oxethazaine JDMF) empowers Oxethazaine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Oxethazaine JDMF during the approval evaluation for pharmaceutical products. At the time of Oxethazaine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Oxethazaine suppliers with JDMF on PharmaCompass.

Oxethazaine WC

A Oxethazaine written confirmation (Oxethazaine WC) is an official document issued by a regulatory agency to a Oxethazaine manufacturer, verifying that the manufacturing facility of a Oxethazaine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Oxethazaine APIs or Oxethazaine finished pharmaceutical products to another nation, regulatory agencies frequently require a Oxethazaine WC (written confirmation) as part of the regulatory process.

click here to find a list of Oxethazaine suppliers with Written Confirmation (WC) on PharmaCompass.

Oxethazaine GMP

Oxethazaine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Oxethazaine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oxethazaine GMP manufacturer or Oxethazaine GMP API supplier for your needs.

Oxethazaine CoA

A Oxethazaine CoA (Certificate of Analysis) is a formal document that attests to Oxethazaine's compliance with Oxethazaine specifications and serves as a tool for batch-level quality control.

Oxethazaine CoA mostly includes findings from lab analyses of a specific batch. For each Oxethazaine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Oxethazaine may be tested according to a variety of international standards, such as European Pharmacopoeia (Oxethazaine EP), Oxethazaine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oxethazaine USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty